These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 4644881)

  • 21. Effect of various diluents on stability of vaccinia virus dilutions.
    Szathmáry J; Hegedüs L; Koller M
    Acta Microbiol Acad Sci Hung; 1971; 18(1):61-7. PubMed ID: 5143504
    [No Abstract]   [Full Text] [Related]  

  • 22. Variola virus and immunity in smallpox. II. Recovery of variola-specific soluble antigens from infected rhesus monkey kidney cells.
    Anthony RL; Daniel RW; Cole JL; Heiner GG; McCrumb FR
    J Infect Dis; 1971 Apr; 123(4):399-405. PubMed ID: 4329345
    [No Abstract]   [Full Text] [Related]  

  • 23. Reversed passive haemagglutination-inhibition method for the estimation of antivaccinia antibodies.
    Nyerges G
    Immunology; 1969 Sep; 17(3):333-7. PubMed ID: 5352004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The kinetics of the in vitro trimming of haemagglutinins from the particles of vaccinia and Ranikhet disease viruses by the lysates of the cells of virus infected CAM cultures.
    Babbar OP; Chowdhury BL
    Indian J Med Res; 1974 Nov; 62(11):1612-8. PubMed ID: 4475663
    [No Abstract]   [Full Text] [Related]  

  • 25. [Relation between antibody formation and immunity against cutaneous vaccinia virus infection in hens].
    Andrzejewski J; Bogunowicz A; Zajac I
    Zentralbl Bakteriol Orig; 1968; 207(3):419-21. PubMed ID: 5745681
    [No Abstract]   [Full Text] [Related]  

  • 26. The significance of the challenge strain in the potency assay of the antivaccinia immunoglobulin preparation.
    Nyerges G; Csukás M; Láng Cs
    Dev Biol Stand; 1974; 27():98-101. PubMed ID: 4463129
    [No Abstract]   [Full Text] [Related]  

  • 27. [Approach to the development of an actovaccine using vaccinia virus as a model].
    Chimishkian KL; Svet-Moldavskiĭ GIa
    Vopr Virusol; 1975; (3):273-8. PubMed ID: 1162946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The significance of the challenge strain in the potency assay of the anti-vaccinia immunoglobulin preparations.
    Nyerges G; Csukás M; Láng CS
    Ann Immunol Hung; 1973; 17():63-5. PubMed ID: 4805815
    [No Abstract]   [Full Text] [Related]  

  • 29. [Laboratory markers of vaccinia virus in the vaccinia pulp, glycerinated vaccine and lyophilized suspension stored for 1 to 8 years at -25 degrees C].
    Mihancea N
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1981; 26(3):191-7. PubMed ID: 7330566
    [No Abstract]   [Full Text] [Related]  

  • 30. [Characterization of viremia in rabbits infected with a neurotropic strain of vaccinia virus].
    Benda R
    Zentralbl Bakteriol Orig A; 1973 May; 223(4):426-35. PubMed ID: 4146818
    [No Abstract]   [Full Text] [Related]  

  • 31. Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene.
    Aldaz-Carroll L; Whitbeck JC; Ponce de Leon M; Lou H; Pannell LK; Lebowitz J; Fogg C; White CL; Moss B; Cohen GH; Eisenberg RJ
    Virology; 2005 Oct; 341(1):59-71. PubMed ID: 16083934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Experiences with improvement of the neutralization reaction with vaccinia virus in chick fibroblast cultures.
    Aksenov OA; Smorodintsev AA
    J Hyg Epidemiol Microbiol Immunol; 1966; 10(4):488-98. PubMed ID: 6006816
    [No Abstract]   [Full Text] [Related]  

  • 33. A method for the purification, concentration and inactivation of vaccinia virus.
    Robinson LC; Kaplan C
    Prog Immunobiol Stand; 1967; 3():170-8. PubMed ID: 5393209
    [No Abstract]   [Full Text] [Related]  

  • 34. [Biological and physicochemical characteristics of DNP of cells, infected with different viruses].
    Peterson OP; Berezina ON; Kozlova IA; Sklianskaia EI
    Vestn Akad Med Nauk SSSR; 1972; 27(6):45-9. PubMed ID: 4674546
    [No Abstract]   [Full Text] [Related]  

  • 35. Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies.
    Weyer J; Rupprecht CE; Mans J; Viljoen GJ; Nel LH
    Vaccine; 2007 May; 25(21):4213-22. PubMed ID: 17434244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isolation and characterization of an IBT-dependent mutant of vaccinia virus.
    Katz E; Winer B; Margalith E; Goldblum N
    J Gen Virol; 1973 Apr; 19(1):161-4. PubMed ID: 4798497
    [No Abstract]   [Full Text] [Related]  

  • 37. Study on the purification of influenza virus vaccine. Filtration of formalin-inactivated influenza virus with Sepharose 6B.
    Tomita S; Asahara T
    Kitasato Arch Exp Med; 1971 Dec; 44(3):185-96. PubMed ID: 5155555
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparative studies on poxvirus strains isolated from camels.
    Tantawi HH; El-Dahaby H; Fahmy LS
    Acta Virol; 1978 Nov; 22(6):451-7. PubMed ID: 35942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Construction and isolation of recombinant MVA.
    Staib C; Drexler I; Sutter G
    Methods Mol Biol; 2004; 269():77-100. PubMed ID: 15114009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification and characterization of the bovine herpesvirus 5 US4 gene and gene products.
    Engelhardt T; Keil GM
    Virology; 1996 Nov; 225(1):126-35. PubMed ID: 8918539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.